Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).
about
New insights into the management of hypertension and cardiovascular risk with Angiotensin receptor blockers: observational studies help us?The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.Office and ambulatory blood pressure control with a fixed-dose combination of candesartan and hydrochlorothiazide in previously uncontrolled hypertensive patients: results of CHILI CU Soon.
P2860
Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Candesartan cilexetil/hydrochl ...... ascular risk (CHILI Triple T).
@ast
Candesartan cilexetil/hydrochl ...... ascular risk (CHILI Triple T).
@en
Candesartan cilexetil/hydrochl ...... o moderate cardiovascular risk
@nl
type
label
Candesartan cilexetil/hydrochl ...... ascular risk (CHILI Triple T).
@ast
Candesartan cilexetil/hydrochl ...... ascular risk (CHILI Triple T).
@en
Candesartan cilexetil/hydrochl ...... o moderate cardiovascular risk
@nl
prefLabel
Candesartan cilexetil/hydrochl ...... ascular risk (CHILI Triple T).
@ast
Candesartan cilexetil/hydrochl ...... ascular risk (CHILI Triple T).
@en
Candesartan cilexetil/hydrochl ...... o moderate cardiovascular risk
@nl
P2860
P356
P1476
Candesartan cilexetil/hydrochl ...... vascular risk (CHILI Triple T)
@en
P2093
Bernhard Landers
Gerd Bönner
P2860
P356
10.2147/VHRM.S17004
P407
P577
2011-02-17T00:00:00Z